Exact sciences corporation stock.

The Exact Sciences Corp (NASDAQ: EXAS) stock price reached the ceiling this week, with shares gaining a sizable 16.38% over the past five days. Most of that value climb came yesterday, with the ...

Exact sciences corporation stock. Things To Know About Exact sciences corporation stock.

Business intelligence is what S&P ratings are all about. This global corporation provides credit ratings on investments, including bonds and the stock market. Before you can understand what a good rating is, it helps to understand the origi...Nov 30, 2023 · 30,994.67. -0.26%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Exact Sciences Corp (EXAS.OQ) real-time stock quotes, news, price and financial information from Reuters to ... 27-Oct-2020 ... ... stock consideration of up to $2.15 billion. The transaction was ... © Exact Sciences Corporation – 5505 Endeavor Lane - Madison, WI 53719.MADISON, Wis., April 10, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2023 financial results after the close of the U.S. financial markets on May 9, 2023.EXAS is the ticker symbol for Exact Sciences Corporation, a company that provides cancer screening and diagnostic test products. The stock price, news, quote, history and performance outlook of EXAS are shown on Yahoo Finance. See the latest earnings …

Discover historical prices for EXAS stock on Yahoo Finance. View daily, weekly or monthly format back to when Exact Sciences Corporation stock was issued. Stock Information · Financial Information · SEC Filings · Quarterly Results ... © Exact Sciences Corporation – 5505 Endeavor Lane - Madison, WI 53719. Powered By ...

16 brokers have issued twelve-month price targets for Exact Sciences' stock. Their EXAS share price targets range from $73.00 to $130.00. On average, they expect the company's share price to reach $96.56 in the next year. This suggests a possible upside of 44.1% from the stock's current price. View analysts price targets for EXAS or view top ...29-Jul-2019 ... ... share in a cash and stock transaction valued at $2.8 billion. The ... Corporation, 441 Charmany Drive, Madison, Wisconsin 53719, or by ...

The number of shares outstanding of the Registrant’s $0.01 par value Common Stock as of February 20, 2023 was178,217,142. ... EXACT SCIENCES CORPORATION ANNUAL REPORT ON FORM 10‑K YEAR ENDED DECEMBER 31, 2022 TABLE OF CONTENTS Page No. Part I Item 1. Business 4 Item 1A. Risk Factors 19Exact Sciences Corporation (together with its subsidiaries, “Exact,” “we,” “us,” “our” or the “Company”) is a leading, global, advanced cancer diagnostics company. We have developed some of the most impactful tests in cancer diagnostics, and we are currently working to develop additional tests, with the goal of03-Nov-2023 ... everyone excited? Whoo. The stock is up. That's good. ... Exact Sciences and chairman and CEO Kevin Conroy. ... sciences commitment to earlier ...Adjusted EBITDA for the three and six months ended June 30, 2021 has been updated accordingly for comparative purposes. Of the $64.5 million and $60.8 million incurred for the three months ended June 30, 2022 and 2021, $56.4 million and $53.9 million is related to stock-based compensation, respectively, and $8.1 million and $6.9 million is ...Company management will host a conference call and webcast on Wednesday, November 1, 2023, at 5 p.m. ET to discuss third-quarter 2023 results. The webcast will be available at exactsciences.com. Domestic callers should dial 888-330-2384 and international callers should dial +1-240-789-2701. The access code for both domestic and international ...

From hereditary cancer testing and earlier cancer screenings to treatment guidance and therapy selection, we aim to offer a comprehensive suite of tests that ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2023 financial results after ...

11-Feb-2020 ... Exact Sciences Announces Fourth-Quarter 2019 Results ; Net income (loss) per share—basic. $. 0.56 ; Net income (loss) per share—diluted. $. 0.54.Exact Sciences exited third-quarter 2021 with cash and cash equivalents, and marketable securities of $1.22 billion compared with $1.31 billion at the end of second-quarter 2021.Exact Sciences Corporation EXAS reported a net loss of 42 cents per share for first-quarter 2023, ... (EW) : Free Stock Analysis Report. Exact Sciences Corporation (EXAS) : Free Stock Analysis ...MADISON - Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that it has filed a lawsuit against Geneoscopy, Inc. in the United States District Court for the District of Delaware. The lawsuit seeks damages and a court order to stop Geneoscopy from making, using, selling, or …Exact Sciences Corp. said it will acquire Thrive Earlier Detection Corp. to gain technology for cancer screening in a deal worth as much as $2.15 billion. The cash and stock agreement will bring ...Board. Exact Sciences schedules third quarter 2023 earnings call. October 09 2023 - 06:00AM. PR Newswire (US) MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a ...

Nov 30, 2022 · Exact Sciences Corp’s stock is NA in 2023, NA in the previous five trading days and up 56.77% in the past year. Currently, Exact Sciences Corp does not have a price-earnings ratio. Exact Sciences Corp’s trailing 12-month revenue is $2.4 billion with a -11.7% net profit margin. Year-over-year quarterly sales growth most recently was 20.1%. Exact Sciences Corporation Raises Revenue Guidance for the Full Year 2023. Nov 02 + 1 more update. Forecast to breakeven in 2025 Oct 26. No longer forecast ... Lead Independent Director exercised options to buy US$363k worth of stock. Jan 19. Insider notifies of intention to sell stock Jan 13. An Intrinsic Calculation For Exact ...About Exact Sciences Corp. ... Stock-based compensation including the incremental fair value of assumed stock awards and accelerated vesting from post-acquisition qualified termination events was $4.2 million and $8.2 million for the three and nine months ended September 30, 2020.On Nov 8, 2019, Exact Sciences completed the acquisition of Genomic Health for a value of approximately $2.8 billion. Prior to merger, Genomic Health was a prominent provider of genomic-based ...Exact Sciences ( NASDAQ: EXAS) said that its next-generation Cologuard screening test for colon cancer showed better cancer specificity and sensitivity compared to the currently marketed test ...Exact Sciences (EXAS) stock is on the rise Friday following news that Guardant Health's (GH) clinical trial didn't go as well as expected. GH is pushing EXAS higher today Source: Shutterstock Exact Sciences (NASDAQ:EXAS) stock is on the ris...

06-Nov-2020 ... K&L Gates also counseled Exact Sciences in a common stock sale of more than eight million shares, resulting in approximately USD $869.2 million ...

Historical daily share price chart and data for Exact Sciences since 2001 adjusted for splits and dividends. The latest closing stock price for Exact ...SWAV stock has gained 41.4% so far this year. ShockWave Medical delivered an earnings surprise of 180.1%, on average, in the last four quarters. McKesson’s earnings per share estimates increased ...Exact Sciences Corp. reported an EPS of $0 in its last earnings report, beating expectations of -$0.471. Following the earnings report the stock price went down -1.669%. Which hedge fund is a major shareholder of Exact Sciences Corp.?Exact Sciences Corp ( NASDAQ:EXAS) reported a 20% increase in total revenue for Q3 2023, reaching $628 million. The company delivered over a million test results, including a record for Cologuard ...Dec 1, 2023 · 16 brokers have issued twelve-month price targets for Exact Sciences' stock. Their EXAS share price targets range from $73.00 to $130.00. On average, they expect the company's share price to reach $96.56 in the next year. This suggests a possible upside of 44.1% from the stock's current price. View analysts price targets for EXAS or view top ... Under the terms of the asset purchase agreement, mdxhealth acquired the Oncotype DX GPS prostate cancer business of Exact Sciences for an aggregate purchase price of up to $100 million, of which ...Exact Sciences Corporation (EXAS.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Exact Sciences Corporation ...SWAV stock has gained 41.4% so far this year. ShockWave Medical delivered an earnings surprise of 180.1%, on average, in the last four quarters. McKesson’s earnings per share estimates increased ...MADISON - Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that it will present new data highlighting the company's novel technology and approaches to early cancer detection at the American Association for Cancer Research (AACR) Annual Meeting 2023, April 14-19, in …

Exact Sciences (EXAS) stock is on the rise Friday following news that Guardant Health's (GH) clinical trial didn't go as well as expected. GH is pushing EXAS higher today Source: Shutterstock Exact Sciences (NASDAQ:EXAS) stock is on the ris...

May 15, 2023 · On Nov 8, 2019, Exact Sciences completed the acquisition of Genomic Health for a value of approximately $2.8 billion. Prior to merger, Genomic Health was a prominent provider of genomic-based ...

Dec 1, 2023 · Sentiment. Exact Sciences (EXAS) has an AI Score of /10 (Buy) because its overall probability of beating the market (S&P 500) in the next 3 months (43.63%) is +42.63% vs. the average probability (%) of US stocks analyzed by our Artificial Intelligence. The AI-powered overall analysis of Exact Sciences (EXAS) is based on the fundamental ... EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is ...Nov 9, 2023 · Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently down 3.17% so far this month. During the month of November, Exact Sciences Corp’s stock price has reached a high of $68.02 and a low of $59.51. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $39.90. Year to date, Exact ... Nov 30, 2023 · 30,994.67. -0.26%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Exact Sciences Corp (EXAS.OQ) real-time stock quotes, news, price and financial information from Reuters to ... Exact Sciences Corp. (EXAS) will release its next earnings report on Feb 20, 2024. In the last quarter Exact Sciences Corp. reported -$0.471 EPS in relation to $0 expected by the market. ... Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including ...Exact Sciences Corporation issued to certain of the selling stockholders of Paradigm an aggregate of 381,047 shares of common stock as initial merger consideration for their ownership in Paradigm. In addition, Exact Sciences Corporation withheld 45,338 shares of common stock payable as additional merger consideration to such selling ...MADISON, Wis. and CAMBRIDGE, Mass., Oct. 27, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) and Thrive Earlier Detection Corp. ("Thrive"), a healthcare company dedicated to incorporating earlier cancer detection into routine medical care, today announced they have entered into a definitive agreement under which Exact …Find the latest Exact Sciences Corporation (EXAS) stock analysis from Seeking Alpha’s top analysts: exclusive research and insights from bulls and bears.Transcript : Exact Sciences Corporation, Q3 2023 Earnings Call, Nov 01, 2023 Nov. 01: CI Exact Sciences Corporation Raises Revenue Guidance for the Full Year 2023 Nov. 01: CI Exact Sciences Corp. Announces Late …

Exact Sciences Corp’s trailing 12-month revenue is $2.4 billion with a -11.7% profit margin. Year-over-year quarterly sales growth most recently was 20.1%. Analysts expect adjusted earnings to reach $-1.363 per share for the current fiscal year. Exact Sciences Corp does not currently pay a dividend.Exact Sciences Corp. reported an EPS of $0 in its last earnings report, beating expectations of -$0.471. Following the earnings report the stock price went down -1.669%. Which hedge fund is a major shareholder of Exact Sciences Corp.?11-Feb-2020 ... Exact Sciences Announces Fourth-Quarter 2019 Results ; Net income (loss) per share—basic. $. 0.56 ; Net income (loss) per share—diluted. $. 0.54.Instagram:https://instagram. making money with stock optionstesla reliability ratinghd building supplybuying bonds now 02-Nov-2023 ... On today's stock market, EXAS stock sank 1.7% to 62.46. Is EXAS Stock Nearing Profitability? Overall, Exact Sciences posted no earnings on ...09-Oct-2023 ... MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests ... webull candlestick chartsnowflakes stock price today Find the latest Exact Sciences Corporation (EXAS) stock analysis from Seeking Alpha’s top analysts: exclusive research and insights from bulls and bears.The average of price targets set by Wall Street analysts indicates a potential upside of 51.7% in Exact Sciences (EXAS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. Find the latest Exact Sciences Corporation (EXAS ... cti engineering Exact Sciences (EXAS) closed the most recent trading day at $66.26, moving -1.27% from the previous trading session. ... Exact Sciences Corporation (EXAS) : Free Stock Analysis Report.Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $602.5 million for the first quarter ended ...Discover historical prices for EXAS stock on Yahoo Finance. View daily, weekly or monthly format back to when Exact Sciences Corporation stock was issued.